Previous 10 | Next 10 |
Athira Pharma has just read out first Phase 2 results in one of two Alzheimer’s trials. Its drug candidate ATH-1017 targets the HGF/MET pathway, a unique approach which has led to promising Phase 1 data. The readout shows efficacy in a subgroup, underlining validity of the ...
Athira Pharma 's (NASDAQ: ATHA) stock crumbled by more than 69.5% as of 10:04 a.m. ET Wednesday after the company reported that results from a phase 2 clinical trial for its drug treating mild to moderate Alzheimer's disease didn't reach statistical significance. The company said th...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: GaudiLab / Shutterstock Exela Technologies (NASDAQ: XELA ) stock is taking off on Wednesday after gaining a new $136 million customer contract . According to a press release from the company, its Exch...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Athira Pharma (NASDAQ: ATHA ) stock is plummeting on Wednesday following the outcome of a Phase 2 clinical trial of fosgonimeton . Fosgonimeton is a treatment for Alzheimer’s disea...
Gainers: 22nd Century Group (XXII) +29%. Wave Life Sciences WVE +16%. Codex DNA (DNAY) +13%. F-star Therapeutics (FSTX) +12%. Sorrento Therapeutics (SRNE) +12%. Losers: Athira Pharma ATHA -70%. Neptune Wellness Solutions NEPT -32%. 4D pharma (LBPS)...
Athira Pharma ATHA -65% as lead asset fails in Alzheimer’s trial. WISeKey International WKEY -43% on reports that it expects revenue growth in semiconductors IoT segment despite shortages in manufacturing. Micro Focus International (MFGP) -18%. Tabula Rasa HealthCar...
Athira Pharma (NASDAQ:ATHA) dropped ~67% in the pre-market Wednesday after the clinical-stage biotech announced that its lead product candidate fosgonimeton (ATH-1017) did not meet key goals in a mid-stage trial involving patients with mild-to-moderate Alzheimer’s disease (AD...
Primary endpoint of change in biomarker ERP P300 latency was not statistically significant for the full study population as combination of fosgonimeton and standard-of-care (AChEIs) given together showed potential diminished effect of fosgonimeton A pre-specified subgroup analys...
BOTHELL, Wash., June 07, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the formation of a Scientific Advisory Board...
Directly or indirectly, peroxynitrite is responsible for much of the damage done to the brain in Alzheimer's disease. As a sigma-1 agonist, blarcamesine limits peroxynitrite formation by inhibiting intracellular calcium release. Blarcamesine likely scavenges peroxynitrite. I...
News, Short Squeeze, Breakout and More Instantly...
Reporting of Topline Results Targeted by End of Third Quarter 2024 Results to be presented in oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) on October 29, 2024, in Madrid, Spain BOTHELL, Wash., July 09, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc (N...
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint...
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy ...